美国 · 股市与财经 · Morningstar

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

来源：Morningstar · 美国 16 小时前

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss In the MEERKAT and SANDCAT studies, vamikibart…

在 Morningstar 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.morningstar.com)

推荐阅读

Microsoft’s Satya Nadella says AI models need an ‘emergency brake’

Business Insider

Satya Nadella says a company's relationship with AI should have trust issues

Pemex Needs Nearly $110 Billion to Hit Mexico's Output Targets

Microsoft's Nadella says AI needs an ‘emergency brake’ that humans control

SA Asks: Is now the time to buy quantum stocks? If so, which ones?

Ship captains and crews transiting the Strait of Hormuz make so much danger pay that they’re ‘almost being viewed as mercenaries’